BRANFORD, Conn. – June 25, 2006 – 454 Life Sciences Corporation, a majority-owned subsidiary of CuraGen Corporation (Nasdaq: CRGN), in collaboration with scientists at Dana Farber Cancer Center and ...

BRANFORD, Conn. – May 31, 2007 – 454 Life Sciences Corporation, in collaboration with scientists at the Human Genome Sequencing Center, Baylor College of Medicine, announced today in Houston, Texas, ...

'This hybrid sequencing strategy has the potential for being the first in years to have a major impact on the sequencing community,' the authors write. Indeed, they estimate the hybrid approach can ...

CuraGen Corporation's majority-owned subsidiary 454 Life Sciences has announced that research on small RNAs, conducted by Cold Spring Harbor Laboratory, has revealed the dual role of the ARGONAUTE 4 ...

CuraGen Corp. subsidiary 454 Life Sciences, a Branford, Conn.-based developer of genome-scale sequencing technologies, today announced that it has obtained an exclusive license for sole use of ...

454 Life Sciences, a Roche company has announced the publication of the 250th peer-reviewed study using the Genome Sequencer System. Researchers are taking advantage of the accuracy and long reads ...

DNA sequencing is a powerful technique firmly entrenched into every aspect of biological research and drug discovery. Recent advances in high throughput capillary sequencing combined with the shotgun ...